Challenges in the Research and Development of Orphan Drugs: A Review
Journal of Pharmaceutical Research International · pp. 1–6 · Published 17 Nov 2022
10.9734/jpri/2022/v34i53B7227Abstract
Pharmaceutical agents which treat rare medical conditions like orphan or rare diseases are called “orphan drugs”. The name ‘orphan’ itself indicates that the pharmaceutical industries are showing less interest in the development and marketing of drugs intended only for a small number of patients. Difficulty in the diagnosis and therapeutic management of rare disease is the major challenge in the development of orphan drug. In recent years, progress has been made in the development of orphan drugs by pharma industries due to enactment of different regulations, administration authorities, tax benefits, marketing rights and public awareness by different countries. This review provides an overview of incentives, marketing rights and administrative authorities of different countries like U.S, European Union, South Korea, Japan, Australia and Taiwan.
Cited by 2
Sandhya Rajaram, Bikash Medhi · Indian Journal of Pharmacology · 2025
Showing 1 of 2 known citations — external sources report more than can currently be individually listed.
Related research
- Antimicrobial Resistance in Primary Health Care Setting: The Prevalence of Multi-Drug Resistant Organisms in Health Centers under the Primary Health Care Corporation PHCC, Qatar — shares topic coverage
- Interactive GIS Based Flood Risk Assessment for Illinois: Enhancing Preparedness, Planning, and Public Awareness — shares topic coverage
- Coverage of Child Right Abuse in Nigerian Newspapers — shares topic coverage
- Navigating Air Quality Assessment: A Holistic Review of Air Quality Index Metrics and Assessment Approaches — shares topic coverage
- Public Awareness of Clear Aligners Orthodontics in India: Insights from a Questionnaire Study — shares topic coverage
Article metrics
Real usage data collected on this platform.
12
Page views
0
PDF downloads
0
Outbound clicks
2
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.